Pfizer Creates First COVID-19 Drug: How It Works

Pfizer has announced Phase 1 trials of an experimental new oral antiviral drug for the treatment of SARS-CoV-2. Tests taking place in the USA. This is stated on website.

Photo: Shutterstock

The oral antiviral drug PF-07321332, a SARS-CoV2-3CL protease inhibitor, has shown potent antiviral activity against SARS-CoV-2 as well as against other coronaviruses, suggesting it could be used in the treatment of COVID-19, as well as potential use to eliminate future coronavirus threats.

“Combating the COVID-19 pandemic requires both prevention through a vaccine and targeted treatment for those who contract the virus. Given the way SARS-CoV-2 mutates and the ongoing global impact of COVID-19, it seems likely that access to therapeutic options will be critical both now and after the pandemic, said Mikael Dolsten, MD, PhD, chief scientific officer and Pfizer President of Global Research, Development and Medicine.

On the subject: In the US, after vaccination against COVID-19, you can get a free donut

“We developed PF-07321332 as a potential oral therapy that could be given at the first sign of infection without requiring patients to be hospitalized. At the same time, Pfizer's intravenous antiviral is a potential new treatment option for hospitalized patients. Together, they can create a comprehensive treatment paradigm that complements vaccination in cases where disease still occurs,” Dolsten added.

Protease inhibitors bind to a viral enzyme (called a protease), preventing the virus from replicating in the cell. Protease inhibitors have been effective in treating other viral pathogens such as HIV and hepatitis C virus, either alone or in combination with other antiviral drugs.

The Phase 1 is a randomized, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability, and pharmacokinetics of PF-07321332.

You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York.

The start of this study is supported by preclinical studies that have demonstrated the antiviral activity of this potential first-in-class anti-SARS-CoV-2 therapeutic designed specifically to suppress the replication of the SARS-CoV-2 virus.

The structure of PF-07321332, along with preclinical data, will be unveiled at the American Chemical Society's Spring COVID-19 meeting on April 6.

Pfizer is also studying the intravenous PF-07304814 investigational protease inhibitor PF-1, which is currently in phase 19b multi-dose trials involving hospitalized participants in COVID-XNUMX clinical trials.

Read also on ForumDaily:

In the US, after vaccination against COVID-19, you can get a free donut

The common cold can suppress the coronavirus: how it will affect the pandemic

A young American woman dies after being vaccinated against COVID-19: doctors insist that this is a coincidence

One COVID-19 vaccine could lead to blood clots

Do you want more important and interesting news about life in the USA and immigration to America? — support us donate! Also subscribe to our page Facebook. Select the “Priority in display” option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram  and Instagram- there is a lot of interesting things there. And join thousands of readers ForumDaily New York — there you will find a lot of interesting and positive information about life in the metropolis.